Proprietary Technologies with Efficient Workflow & Quick Lab Turnaround Time

Report Icon

View Sample Report

View Now

Learn More About How These Technologies Lead to Better Results

Precipio White Logo

contact us now

contact us
Genetic Research

Proprietary Technologies

Precipio has developed several cutting-edge technologies to provide unparalleled diagnostic accuracy. These technologies help address issues from low cellularity, false negatives in cytogenetics, and slow TAT’s for molecular testing.

HemeScreen, and IV-Cell were developed in our lab to solve common industry challenges through simplified workflows, resulting in faster turnaround times in molecular and cytogenetic testing.
Rev-CI was developed to address the complications of other commercial cell enrichment technologies that can hinder diagnostic accuracy. The Rev-CI proprietary procedure selectively enriches samples for cells of interest enabling conclusive FISH results for up to 98% of samples. This allows sub-classification of B-Cell lymphomas and definitive prognosis of Multiple Myelomas.

Only Precipio offers these solutions.

HemeScreen Panel Overview

Precipio has developed a Research Use Only (RUO) proprietary hematologic malignancy screening panel. The screening panel currently includes JAK2 (V617F), JAK2 Exon 12 & 13, MPL & CALR. The panel utilizes a rapid and cost-effective mutation screening technology called High Resolution Melt analysis (HRM).